Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The osteoporotic niche as a metabolic sanctuary for breast cancer dormancy and reactivation: A mechanistic perspective.

iScience·2026
Same author

Expanding roles of cGAS-STING signaling in neuroinflammation.

The Journal of clinical investigation·2026
Same author

Genome-wide analysis of expansin and aquaporin genes and their association with auxin-related metabolites during flower opening in <i>Lonicera macranthoides</i>.

Frontiers in plant science·2026
Same author

AI guided discovery of a murine model of asymptomatic Alzheimer's disease.

Acta neuropathologica communications·2026
Same author

cGAS inhibition delays TDP-43-driven ALS Pathogenesis.

bioRxiv : the preprint server for biology·2026
Same author

A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO.

mAbs·2026

Related Experiment Video

Updated: Mar 17, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

Chemically Programmed Bispecific Antibodies in Diabody Format.

Even Walseng1, Christopher G Nelson2, Junpeng Qi1

  • 1From the Departments of Cancer Biology.

The Journal of Biological Chemistry
|July 23, 2016
PubMed
Summary

Chemically programmed bispecific antibodies (biAbs) offer a modular platform to direct cytotoxic T cells against cancer cells. This novel approach enables targeted small molecules to harness immunotherapy without harming healthy tissues.

Keywords:
T-cellantibody engineeringcancer therapychemical modificationfolateimmunotherapyovarian cancer

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.7K
Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

8.3K

Related Experiment Videos

Last Updated: Mar 17, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.7K
Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

8.3K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Bispecific antibodies (biAbs) are engineered proteins that can bind to two different targets simultaneously.
  • Chemically programmed biAbs offer a flexible approach to engage immune effector cells with targeted therapies.
  • Current biAbs face challenges in modularity and precise targeting.

Purpose of the Study:

  • To develop a novel platform of chemically programmed bispecific antibodies (biAbs) for cancer immunotherapy.
  • To merge antibody technologies for enhanced modularity and effector cell recruitment.
  • To demonstrate the efficacy of this platform in targeting cancer cells expressing specific receptors.

Main Methods:

  • Combined humanized anti-hapten mAb (h38C2) and anti-CD3 mAb (v9) in a Dual-Affinity Re-Targeting (DART) diabody format.
  • Developed chemically programmed biAbs by equipping DARTs with hapten-derivatized small molecules.
  • Validated the platform using hapten-folate to target folate receptor 1 (FOLR1)-expressing ovarian cancer cells in vitro and in vivo.

Main Results:

  • Successfully created chemically programmed biAbs (h38C2 × v9 DARTs) with a modular design.
  • Demonstrated that these biAbs can be equipped with tumor-targeting small molecules without systemic toxicity.
  • Showcased selective and potent elimination of FOLR1-expressing ovarian cancer cells in vitro and in vivo.

Conclusions:

  • Chemically programmed biAbs in DART format provide a highly modular and versatile platform for cancer immunotherapy.
  • This approach allows tumor-targeting compounds to effectively engage cytotoxic T cells for cancer cell elimination.
  • The platform offers broad utility for both target and effector cell engagement, advancing targeted cancer treatment.